ACI-Portland Program Registration
This program has already taken place, to find information on upcoming programs, please check here.Program Agenda
February 21, 2019 ProgramCredit information to be announced. Click here for more detailed CME, CNE and CPE information and program objectives.
Presentations include time for Audience Response System (ARS)-assisted audience interaction as well as general question and answer time.
3:30 – 4:30 p.m.
Check-in, Onsite Registration and Networking
Session I: Introduction to Cancer Immunotherapy
4:30 – 4:35 p.m.
Welcome, Introduction, SITC Resources
4:35 – 5:05 p.m.
Basic Principles of Cancer ImmunotherapyAndrew J. Gunderson, PhD – Earle A. Chiles Research Institute, Providence Cancer Institute
5:05 – 5:10 p.m.
Session II: Immunotherapy in Practice
Concurrent Session 1
5:10 – 5:50 p.m.
Immunotherapy for the Treatment of Lung CancerKhaled A. Tolba, MD, MBBCh – Oregon Health & Science University
Immunotherapy for the Treatment of MelanomaWalter J. Urba, MD – Earle A. Chiles Research Institute, Providence Cancer Institute
5:50 – 5:55 p.m.
Concurrent Session 2
5:55 – 6:35 p.m.
Immunotherapy for the Treatment of Head and Neck CancerRom Leidner, MD – Earle A. Chiles Research Institute, Providence Cancer Institute
Immunotherapy for the Treatment of Genitourinary MalignanciesBrendan D. Curti, MD – Earle A. Chiles Research Institute, Providence Cancer Institute
6:35 – 7:05 p.m.
Joint Session (all attendees)
7:05 – 7:45 p.m.
Immunotherapy for the Treatment of Hematologic MalignanciesJohn E. Godwin, MD – Earle A. Chiles Research Institute, Providence Cancer Institute
Session III: Barriers in Practice
7:45 – 8:30 p.m.
Practical Barriers in Cancer Immunotherapy TreatmentJennie R. Crews, MD, MMM – Seattle Cancer Care AlliancePanel Jennie R. Crews, MD, MMM – Seattle Cancer Care AllianceBrendan D. Curti, MD – Earle A. Chiles Research Institute, Providence Cancer InstituteJoanne T. Eddington, FNP – Providence Cancer InstituteSamuel Jacobson, PharmD – Providence Cancer Institute Kevin Olson, MD – Providence Cancer Institute
Session IV: The Future of Cancer Immunotherapy
8:30 – 8:55 p.m.
What’s Next for Cancer Immunotherapy?Bernard A. Fox, PhD – Earle A. Chiles Research Institute, Providence Cancer Institute
8:55 – 9:00 p.m.
Specifically designed by the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, nurse practitioners, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) programs are introductory, CE- and MOC-accredited programs. Presented by leading and local authorities in tumor immunology and cancer immunotherapy, these 4.5 hour programs will facilitate understanding of:
Attendees will also have an opportunity for connecting with regional experts in the immunotherapy field at the live event, through four quarterly webinars, and indefinitely through a dedicated online community forum. These connections will serve as ongoing resources while clinical oncologists and other healthcare providers incorporate immunotherapy into practice.
For more information, including program objectives, click here.
View the SITC Meeting Code of Conduct.
The 2018-2019 Advances in Cancer Immunotherapy™ series is brought to you in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association.
Download PDF Flyer
Embassy Suites by Hilton Portland Downtown319 SW Pine StreetPortland, OR 97204
Participation in this free online pre-program course is strongly recommended as it contains information that will not be covered at the program on February 21, 2019.
This updated, interactive course provides foundational knowledge that is necessary for understanding cancer immunotherapy content that will be discussed at the in-person program. Upon completion of the course, participants can earn continuing education credits (CME, CNE and CPE credits are available).
Click here to access this free course.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com